Fabry Disease — The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
Citation(s)
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study